Results 71 to 80 of about 79,407 (254)

Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV: Results from the ANRS CO4 French hospital database on HIV

open access: yesInternational Journal of Cancer, EarlyView.
What's New? This large nation‐wide cohort study provides a comprehensive 20‐year analysis of cancer trends among people living with HIV in France, highlighting persistent excess risks for virus‐related cancers despite effective antiretroviral therapy and immune restoration.
Sophie Grabar   +14 more
wiley   +1 more source

Treatment failure and drug resistance in HIV‐positive patients on tenofovir‐based first‐line antiretroviral therapy in western Kenya

open access: yesJournal of the International AIDS Society, 2016
Introduction Tenofovir‐based first‐line antiretroviral therapy (ART) is recommended globally. To evaluate the impact of its incorporation into the World Health Organization (WHO) guidelines, we examined treatment failure and drug resistance among a ...
Katherine Brooks   +10 more
doaj   +1 more source

Mitotherapy inhibits against tenofovir induced nephrotoxicity on rat renal proximal tubular cells

open access: yesBiochemistry and Biophysics Reports
Tenofovir, as nucleotide reverse transcriptase inhibitors (NRTIs), is used to prevent and cure HIV/AIDS. Ample evidence confirmed that the nephrotoxicity of tenofovir has been linked to mitochondrial dysfunction.
Mir-Jamal Hosseini   +5 more
doaj   +1 more source

Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. [PDF]

open access: yes, 2019
"Vaults" are ubiquitously expressed endogenous ribonucleoprotein nanoparticles with potential utility for targeted drug delivery. Here, we show that recombinant human vault nanoparticles are readily engulfed by certain key human peripheral blood ...
Anton, Peter A   +11 more
core  

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study

open access: yesAIDS (London), 2021
Supplemental Digital Content is available in the text Objective: Recycling tenofovir and lamivudine/emtricitabine (XTC) with dolutegravir would provide a more tolerable, affordable, and scalable second-line regimen than dolutegravir with an optimized ...
C. Keene   +17 more
semanticscholar   +1 more source

Upper Airway Obstruction due to Kaposi Sarcoma—Presenting Sign of HIV: Case Report and Review

open access: yesThe Laryngoscope, EarlyView.
This study presents a case of undiagnosed HIV presenting with Kaposi sarcoma (KS) of the head and neck with acute upper airway obstruction (UAO) and provides an updated scoping literature review to examine the patient characteristics, lesion characteristics, interventions, and outcomes of KS cases with UAO from the pharynx, larynx, and/or trachea.
Zachary A. Wykoff   +3 more
wiley   +1 more source

Mucosal effects of tenofovir 1% gel

open access: yeseLife, 2015
Tenofovir gel is being evaluated for vaginal and rectal pre-exposure prophylaxis against HIV transmission. Because this is a new prevention strategy, we broadly assessed its effects on the mucosa.
Florian Hladik   +19 more
doaj   +1 more source

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. [PDF]

open access: yes, 2015
Chronic kidney disease (CKD) is a major health issue for HIV-positive individuals, associated with increased morbidity and mortality. Development and implementation of a risk score model for CKD would allow comparison of the risks and benefits of adding ...
D:A:D study group, .   +18 more
core  

Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study. [PDF]

open access: yes, 2017
BackgroundThere is ongoing controversy regarding abacavir use in the treatment of HIV infection and the risk of subsequent development of cardiovascular disease.
Baxi, Sanjiv M   +3 more
core   +3 more sources

Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B

open access: yesNew England Journal of Medicine, 2018
BACKGROUND Pregnant women with an elevated viral load of hepatitis B virus (HBV) have a risk of transmitting infection to their infants, despite the infants' receiving hepatitis B immune globulin.
G. Jourdain   +37 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy